Metronomics Global Health Initiative

Home page > Publications > Papers of Interest > Metronomic in adult

Metronomic in adult

category count 20 billets

Cancer research, a field on the verge of a paradigm shift?

In this perspective piece, Ido Goldstein, Shalom Madar et Varda Rotter from the Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot , Israel, analyze the roots of the paradigm on which cancer research is based. Then, they propose that the field of cancer research would benefit from integrating normal and "out of the (...)

metronomic temzolomide and propranol for refractory metastatic paraganglioma

Miguel-Angel Díaz-Castellanos, Karina Villar Gómez de las Heras, Tamara Díaz-Redondo, Encarnación González-Flores, Virginia Albiñana and Luisa-María Botellafrom the PHEiPAS, Castellón de la Plana, Alianza VHL, Centro Cívico Rogelio Soto, Sabadell Sanidad Castilla-La Mancha, Toledo, Servicio de Oncología, Hospital Universitario Carlos Haya, Málaga, Servicio de (...)

Are Beta Blockers New Potential Anticancer Agents?

Shahid Akbar and Mansour Saleh Alsharidah respectively from the Department of Pharmacology, College of Pharmacy, and Department of Physiology, College of Medicine; Qassim University, Buraidah, in Saudi Arabia have just published a review entitled "Are Beta Blockers New Potential Anticancer Agents?" in the Asian Pacific Journal of Cancer Prevention (...)

De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?

Palma Fedele, Valeria Sanna, Alessandro Fancellu, Antonella Marino, Nicola Calvani, and Saverio Cinierid from the Medical Oncology, Dario Camberlingo Hospital, Francavilla Fontana , the Medical Oncology, Hospital of Sassari, Sassari, the Department of Medical, Surgical and Experimental Sciences, Unit of General Surgery, University of Sassari, and the (...)

Drug Repurposing in Oncology—patient and health systems opportunities

The cost of cancer drugs is going through the roof. Reconsidering the large arsenal of drugs already available for other diseases as options for treating cancer is a unique opportunity for patients and for national healthcare systems. The continuing reduction in the cost of DNA sequencing is paving the way for ‘precision medicine’, and an increasing (...)

Editorial in JASA : Metronomic chemotherapy: an alternative and effective means of chemotherapy, ideal for developing countries.

Dr Hemonta Dutta, Associate Professor and in-charge of Pediatric Surgery, in the Assam Medical College & Hospital in Dibrugarh and MGHI member has recently published a recent editorial in the Journal of the Association odf Surgeons of Assam in Idian, entitled : Metronomic chemotherapy: an alternative and effective means of chemotherapy, ideal for (...)

Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy.

Y. Shaked and al. from the Israel Institute of Technology, The University of Texas M. D. Anderson Cancer Center and the Sunnybrook Research Institute have just published in Cancer Research an article entitled: Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy where they show the impact of metronomic (...)

Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.

In a recent review entitled : Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy, Junjie Wu and David Waxman from the Department of Biology, Division of Cell and Molecular Biology, Boston University, Boston USA review the data about metronomic chemotherapy (MC) and its impact on immunity Indeed, some (...)

Metformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis

In this hypothesis paper the authors Jorge Eduardo Duque, Juliana Velez, Ismael Samudio and Enoch Lai from the Grupo de Terapia Celular y Molecular, Pontificia Universidad Javeriana, Bogotá DC, Colombia, the Centro Oncológico de Antioquia, Medellín, Colombia and the Shuang Ho Medical Hospital, Taipei Medical University, Taipei, Taiwan disucss the rationale (...)

Metronomic chemotherapy : new rationale for new direction

Nat Rev Clin Oncol. 2010 Aug;7(8):455-65. Epub 2010 Jun 8. Metronomic chemotherapy: new rationale for new directions. Pasquier E, Kavallaris M, André N. Tumor angiogenesis is recognized as a major therapeutic target in the fight against cancer. The key involvement of angiogenesis in tumor growth and metastasis has started to redefine chemotherapy and (...)